India, June 23 -- Across the pharmaceutical industry, AI adoption has accelerated rapidly. Models now support molecular design, clinical trial optimisation, process parameter prediction, and regulatory document generation. Individual use cases increasingly demonstrate clear value in controlled conditions.

Yet most initiatives remain confined to pilots. The anticipated gains in productivity, speed, and decision quality are not being realised consistently. Organisations invest heavily in AI capabilities without seeing proportional improvements in development timelines or operational efficiency.

This pattern is not explained by immature technology. It reflects something more structural: AI is being deployed into environments designed for m...